Clinical Updates in Hereditary Breast Cancer: Highlights From Vienna 2023

Do you know how to select the optimal treatment for a patient with early breast cancer who is eligible for PARP inhibitor and CDK4/6 inhibitor therapy? Credit available for this activity expires: 3/29/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/990176?ecd=bdc_podcast_libsyn_mscpedu